Pioneering A New Children’s Food Allergy Treatment
With the evolution of biotechnology, addressing allergy treatments for children offers hope for a future where the young can lead lives unrestricted by common food allergens.
A pre-clinical stage Biotech Company aimed to develop its first product for novel food allergy treatment in children through clinical proof of concept before partnering with a global pharmaceutical firm and its currently raising capital to support pre-clinical development program.
With the collaborative assistance of Biointelect, the company’s venture to secure investors was strategically streamlined, ensuring their pioneering approach to children’s food allergy treatments was robustly supported, well-researched, and optimally positioned in the market.
Nanoparticle Drug Reformation: A Biointelect Product Development Strategy
With oncology treatments rapidly growing in interest, the quest to refine and perfect drug delivery mechanisms is paramount. Utilising nanoparticles, a biotech company stands on the verge of reformulating three approved oncology drugs, targeting the expansive US and EU markets.
Biointelect has played a critical role in sculpting the company’s strategy, from inception to investor readiness. It is with Biointelect’s assistance that the biotech company could pivot from concept to a formidable market contender, with a clear and strategic vision for investor engagement.
HTA Roadmap For a New Vaccine in Australia
The landscape of vaccines in Australia is marked by stringent guidelines and a competitive marketplace and above all a focus on patient outcomes.
Biointelect partnered with a pharmaceutical company, well-versed in the Australian market but new to the vaccine domain, to develop a roadmap that would not only introduce their new vaccine but also potentially secure it a coveted position on the National Immunisation Program (NIP) with premium pricing.
Developing a Winning Business Case: Securing NHMRC Grant for an Antibiotic Solution
Antibiotic resistance is a looming global health challenge, with the ESKAPE pathogens leading the charge. Amid this urgent need, a university research group has broken new ground with a patented product that promises to dismantle this resistance.
Biointelect’s partnership was enlisted to bolster their pursuit of the esteemed NHMRC Development Grant, offering an integrated approach leading to a strengthened grant application, optimised strategy, and subsequently, successful grant acquisition.
